Welcome to our dedicated page for Bicycle Therapeutics SEC filings (Ticker: BCYC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bicycle Therapeutics plc (NASDAQ: BCYC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Bicycle Therapeutics is a clinical-stage pharmaceutical company developing Bicycle molecules, Bicycle Drug Conjugates (BDC) and Bicycle Radioconjugates (BRC), and its filings offer detailed insight into its operations, governance and financial condition.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand how the company describes its Bicycle technology platform, clinical pipeline, collaboration revenue, research and development expenses, and other key aspects of its biotechnology business. Current reports on Form 8-K, such as those furnished for quarterly financial results and Board of Directors changes, provide timely information on material events, including clinical updates, cost realignment actions, and governance developments.
Because BCYC is listed on The Nasdaq Stock Market LLC through American Depositary Shares, its SEC filings also detail the securities registered under Section 12(b) of the Exchange Act and related listing information. Users interested in director and executive matters can look to proxy materials and 8-K items addressing appointments, compensation policies and inducement equity awards granted under the company’s 2024 Inducement Plan.
On Stock Titan, each BCYC filing is accompanied by AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify disclosures related to clinical trial progress, collaboration agreements, and financial runway commentary. The platform also surfaces insider-related filings such as Form 4 when available, enabling users to monitor reportable transactions by directors and officers alongside the company’s broader SEC reporting history.
Bicycle Therapeutics (BCYC) reported a larger quarterly loss while maintaining a strong cash position. For the three months ended September 30, 2025, collaboration revenue rose to $11.7 million from $2.7 million a year ago, driven by $6.5 million recognized upon termination of the Genentech collaboration and a $2.0 million milestone from Ionis tied to IND acceptance. Operating expenses were $77.3 million versus $66.5 million, reflecting pipeline advancement. Net loss was $59.1 million, or $0.85 per share, compared with $50.8 million, or $0.74 per share, last year.
Cash and cash equivalents were $648.3 million as of September 30, 2025. Deferred revenue totaled $86.4 million, including balances from Bayer ($40.4 million), Novartis ($42.1 million) and Ionis ($3.8 million). The company recorded $7.6 million of U.K. R&D incentives in the quarter and held $67.3 million receivable; $38.2 million was collected in October 2025. In August, Bicycle launched cost reduction initiatives targeting ~30% lower planned operating costs over its runway, including a workforce reduction of ~25%, with $4.1 million in Q3 charges.
Bicycle Therapeutics plc (BCYC) furnished an 8-K announcing quarterly results. The company reported it issued a press release covering financial results for the fiscal quarter ended September 30, 2025, along with other business highlights. The press release is furnished as Exhibit 99.1 and incorporated by reference. The Item 2.02 information, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act.
American Depositary Shares, each representing one ordinary share, trade on Nasdaq under the symbol BCYC.
Insider sale tied to RSU tax withholding; small net reduction in holdings. The CEO and director Kevin Lee reported two sell transactions on
Bicycle Therapeutics PLC (BCYC) reported two insider sales by Chief Technology Officer Michael Skynner tied to restricted stock unit vesting. On
The filings state these were mandatory "sell-to-cover" transactions executed to satisfy statutory tax withholding required by his award agreement rather than discretionary sales. After the transactions his direct beneficial ownership is reported as 118,277 ordinary shares.
Reporting person: Alistair Milnes, Chief Operating Officer of Bicycle Therapeutics PLC (BCYC), reported two required "sell to cover" stock sales tied to the vesting and settlement of restricted stock units. On
Bicycle Therapeutics (BCYC) reported insider sales by Michael Charles Hannay, the company's Chief Product & Supply Chain Officer and a director. He recorded sales on
Bicycle Therapeutics plc (BCYC) Chief Financial Officer Alethia Young reported sale of ordinary shares on
The report notes the 217-share sale was mandatory under the award agreement to satisfy statutory tax withholding on vested restricted stock units, while the 265-share sale followed a trading plan adopted on
Bicycle Therapeutics PLC (BCYC) Chief Accounting Officer Travis Thompson reported two routine share sales tied to the vesting and settlement of restricted stock units. On
Bicycle Therapeutics plc (BCYC) director Robert Charles Swanton reported a sale of 102 ordinary shares on
Bicycle Therapeutics plc (BCYC) filed a Form 144 notice reporting a proposed sale of 102 shares of common stock through Stifel Nicolaus & Company Inc with an aggregate market value of $872, intended for sale on 10/02/2025 on Nasdaq. The filing discloses that 218 shares were acquired on 10/02/2025 as Restricted Stock Units from the issuer and were paid as equity compensation. The form also reports that the filer sold 411 shares on 07/02/2025 for gross proceeds of $3,058. The notice includes the statutory representation that the seller does not possess undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Bicycle Therapeutics (BCYC)?
What is the market cap of Bicycle Therapeutics (BCYC)?
